Myriad Genetics to Acquire Counsyl for $375MMay 29, 2018
May 29, 2018
GenomeWeb – Staff Reporter
NEW YORK (GenomeWeb) — Myriad Genetics is acquiring genetic screening firm Counsyl for $375 million in cash and common stock, the molecular diagnostics firm said last night. The move is a bid to bolster its position in the women’s health space.
The acquisition will allow Myriad, a leader in the hereditary cancer genetic screening market, to expand into carrier screening with Counsyl’s Foresight test, which covers more than 175 clinically actionable conditions across ethnicities, and into the rapidly growing noninvasive prenatal screening market with Counsyl’s Prelude test.News. Bookmark the permalink. ← Hospitals Explore New Models for Labs Post-PAMA NMG at Executive War College in New Orleans →